Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer

BACKGROUND: Durvalumab is an immune checkpoint Inhibitor (ICIs) that is used in the treatment of malignant tumors, such as lung cancer and melanoma. ICIs are associated with immune-related adverse events including autoimmune encephalitis, although both paraneoplastic phenomena and ICI treatment may...

Descripción completa

Detalles Bibliográficos
Autores principales: Moss, Thomas T., Stavem, Knut, Aandahl, Astrid, Gløersen, Anne S., Grønberg, Bjørn H., Neumann, Kirill, Vedeler, Christian A., Lundqvist, Christofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613972/
https://www.ncbi.nlm.nih.gov/pubmed/37908347
http://dx.doi.org/10.3389/fimmu.2023.1278761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613972/
https://www.ncbi.nlm.nih.gov/pubmed/37908347
http://dx.doi.org/10.3389/fimmu.2023.1278761

Ejemplares similares